Emily Rafferty - Evolent Health Executive Success
| EVH Stock | USD 3.23 0.01 0.31% |
Executive
Emily Rafferty is Executive Success of Evolent Health
| Age | 43 |
| Address | 1812 N. Moore Street, Arlington, VA, United States, 22209 |
| Phone | 571 389 6000 |
| Web | https://www.evolent.com |
Evolent Health Management Efficiency
The current Return On Tangible Assets is estimated to decrease to -0.08. The current Return On Capital Employed is estimated to decrease to -0.02. As of now, Evolent Health's Other Current Assets are increasing as compared to previous years. The Evolent Health's current Intangible Assets is estimated to increase to about 821.3 M, while Non Currrent Assets Other are projected to decrease to under 25.9 M. Evolent Health's management efficiency ratios could be used to measure how well Evolent Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Christine Sheehy | MeiraGTx Holdings PLC | 59 | |
| David Rubinstein | MeiraGTx Holdings PLC | N/A | |
| Kerry Perez | AMN Healthcare Services | N/A | |
| Michael MD | Nutex Health | 55 | |
| Jeff Decker | AMN Healthcare Services | N/A | |
| Margaret Ancona | Myriad Genetics | 55 | |
| Kathleen Ford | Kura Oncology | 79 | |
| Justin Hunter | Myriad Genetics | N/A | |
| James JD | ArriVent BioPharma Common | 54 | |
| Mercedes Kelemen | Butterfly Network | N/A | |
| Samraat Raha | Myriad Genetics | 53 | |
| Megan Carlson | Butterfly Network | 43 | |
| Robert JD | MeiraGTx Holdings PLC | 50 | |
| Matthew Scalo | Myriad Genetics | N/A | |
| Arthur Newman | HealthStream | 77 | |
| Jennifer Fox | Myriad Genetics | 52 | |
| Stuart Naylor | MeiraGTx Holdings PLC | 63 | |
| Glenn Farrell | Myriad Genetics | N/A | |
| Mollie MD | Kura Oncology | 48 | |
| Ben Wheeler | Myriad Genetics | N/A | |
| Michael JD | HealthStream | 50 | |
Management Performance
| Return On Equity | -0.12 | ||||
| Return On Asset | 0.0012 |
Evolent Health Leadership Team
Elected by the shareholders, the Evolent Health's board of directors comprises two types of representatives: Evolent Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolent. The board's role is to monitor Evolent Health's management team and ensure that shareholders' interests are well served. Evolent Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolent Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General Officer | ||
| Geoff McHugh, Chief Officer | ||
| Thomas Peterson, Chief Operating Officer | ||
| Katie Cook, Chief Officer | ||
| Elizabeth Cato, Utilization Director | ||
| Robert Cruz, Chief Officer | ||
| Dan McCarthy, CEO President | ||
| John MD, Chief Officer | ||
| Nicholas McGrane, Executive Vice President of Corporate Performance | ||
| Bridget Duffy, Independent Director | ||
| Tunde Sotunde, Independent Director | ||
| Andrew MD, Chief Advisor | ||
| MAAA FSA, Chief Officer | ||
| Emily Rafferty, Executive Success | ||
| Bruce Felt, Independent Director | ||
| John Johnson, Chief Financial Officer | ||
| M Duffy, Independent Director | ||
| John Way, Chief Suite | ||
| Craig Barbarosh, Independent Director | ||
| Steve Tutewohl, Chief Operating Officer | ||
| Cheryl Scott, Lead Independent Director | ||
| Jordan Silvergleid, Chief Officer | ||
| Richard Cochran, Market President | ||
| Seth Blackley, Chief Executive Officer, Co-Founder, Director | ||
| Frank Williams, Co-Founder, CEO, Director and Chairman of Nominating and Governance Committee | ||
| Jonathan Weinberg, General Counsel | ||
| David Farner, Director | ||
| Aammaad Shams, Interim Principal Accounting Officer and Corporate Controller | ||
| Jessica Somers, Sr Devel | ||
| Seth Frank, Vice Relations | ||
| Mark Mannion, Senior Finance | ||
| Scott Pritchard, President Suite | ||
| Mario Ramos, Chief Officer | ||
| Peter Grua, Independent Director | ||
| Heather Orth, Market President | ||
| David Lim, Chief Officer | ||
| Diane Holder, Director | ||
| Michael DAmato, Independent Director | ||
| Kali Beyah, Chief Officer | ||
| Jessica White, Chief Officer | ||
| Kim Keck, Independent Director | ||
| MPH MD, Chief Officer |
Evolent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolent Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.12 | ||||
| Return On Asset | 0.0012 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 1.33 B | ||||
| Shares Outstanding | 111.6 M | ||||
| Shares Owned By Insiders | 1.65 % | ||||
| Shares Owned By Institutions | 98.35 % | ||||
| Number Of Shares Shorted | 19.13 M | ||||
| Price To Earning | (13.88) X |
Currently Active Assets on Macroaxis
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is there potential for Health Care Technology market expansion? Will Evolent introduce new products? Factors like these will boost the valuation of Evolent Health. Projected growth potential of Evolent fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Evolent Health requires distinguishing between market price and book value, where the latter reflects Evolent's accounting equity. The concept of intrinsic value—what Evolent Health's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Evolent Health's price substantially above or below its fundamental value.
It's important to distinguish between Evolent Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evolent Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Evolent Health's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.